| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | 0.27 | 3e-06 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.25 | 4e-05 |
| mRNA | Docetaxel | GDSC1000 | pan-cancer | AAC | 0.14 | 7e-05 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.21 | 0.0002 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0007 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.002 |
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | 0.2 | 0.002 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | ELCPK | CTRPv2 | pan-cancer | AAC | 0.16 | 0.003 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.089 | 0.003 |